Pieris Ponders Future As AstraZeneca Exits Asthma Pact
Trial Of Elarekibep Halted Over ‘Lung Findings’
With a Phase II gastric cancer asset discontinued for financial reasons last year, the pipeline at Pieris is looking very bare now that AstraZeneca has discontinued a mid-stage trial of its asthma candidate elarekibep.
